Mark A. Giembycz
Airways Inflammation Research Group
Departments of Physiology and Pharmacology
Institute of Infection
Immunity and Inflammation
Canada
Name/email consistency: high
- Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Giembycz, M.A., Newton, R. Handb. Exp. Pharmacol (2011)
- An estimation of beta 2-adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilators. Giembycz, M.A. Br. J. Pharmacol. (2009)
- A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Giembycz, M.A., Kaur, M., Leigh, R., Newton, R. Br. J. Pharmacol. (2008)
- Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Giembycz, M.A. Br. J. Pharmacol. (2008)
- Beyond the dogma: novel beta2-adrenoceptor signalling in the airways. Giembycz, M.A., Newton, R. Eur. Respir. J. (2006)
- An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Giembycz, M.A. Br. J. Clin. Pharmacol (2006)
- Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?. Giembycz, M.A., Smith, S.J. Curr. Pharm. Des. (2006)
- Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Giembycz, M.A. Curr. Opin. Pharmacol (2005)
- Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Giembycz, M.A. Proc. Am. Thorac. Soc (2005)